Case Study
The Case Study section of Insulin concludes with questions about the case being presented. A summary of the responses we receive for each case study will appear in the next issue along with a new case study (and its accompanying questions).

Respond to Case Study

The deadline for your response is March 15, 2010. By answering these questions, you agree that Insulin can use your answers in an aggregated form.

All fields required

 

1. Which of the patient’s HIV medications is least likely to cause adverse metabolic or cardiovascular disease?


Lamivudine (nucleoside reverse transcriptase inhibitor)


2. Which of the following is a risk factor for the development of type 2 DM in this patient?


Family history
HIV infection
Medication
All of the above

3. Which of the following oral medications is contraindicated in a patient with HIV on antiretroviral therapy?
Metformin
Pioglitazone
Glipizide
Repaglinide
None of the above

4. The most appropriate choice of lipid-lowering medication in this patient is:

Simvastatin 40 mg once daily
Lovastatin 80 mg once daily
Atorvastatin 80 mg once daily

5. Your details

Salutation:
First:
Last:
Email Address:
Institution:
Occupation:
.
Insulin may display my name and responses to this case study.
Insulin may email me at this address about site changes, promotions and related information.

Copyright © 2010 Excerpta Medica Inc.
Affiliate Links: